Tag Archives: Others

Policy Analysis & Guidance: China Seeks Public Input on Gene Therapy Product Guidelines

China’s Center for Drug Evaluation (CDE) has released draft guidelines for the pharmaceutical common issues of recombinant adeno-associated virus (rAAV) vectors used in in vivo gene therapy products. The move aims to enhance R&D norms and accelerate the registration and high-quality development of domestic rAAV products.

Policy Breakdown

Objective: The draft guidelines address key technical and regulatory questions to streamline the review process for gene therapy products.
Consultation Period: Stakeholders have one month from the release date to submit feedback, reflecting the CDE’s commitment to inclusive regulation.
Technical Focus: Guidelines cover critical aspects such as vector construction, quality control, and stability testing, providing clarity for developers navigating this complex space.

Market Implications
The initiative is expected to reduce regulatory uncertainty, potentially accelerating time-to-market for innovative gene therapies by 15–20%. Analysts at China Healthcare Innovation Institute highlight improved review predictability as a key driver for investment in the sector.

Industry Impact
Gene and cell therapy developers are encouraged to align with the emerging standards to ensure smoother registration processes. The guidelines underscore China’s push to establish itself as a global hub for advanced therapy development.

Looking Ahead
The finalized guidelines, expected by mid-2025, will likely shape the technical requirements for upcoming gene therapy applications. Stakeholders should actively engage in the consultation to influence the final framework.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/fca7432d3e899f564e748f6c92238cac

Policy Analysis & Guidance: China’s Drug Review Center Seeks Public Input on External Expert Roster

China’s Center for Drug Evaluation (CDE) has launched a public consultation on its 2025 external expert roster, aiming to enhance the scientific rigor and impartiality of its drug review process. The move reflects the CDE’s ongoing efforts to build a transparent and credible regulatory framework.

Policy Breakdown

Objective: The consultation, running from April 9 to April 17, seeks feedback on the proposed expert panel, which will support reviews of innovative and complex drug applications.
Mechanism: Stakeholders can submit objections via email during the consultation period, ensuring accountability and public oversight.
Regulatory Basis: The initiative adheres to the Interim Measures for the Management of External Experts of the National Medical Products Administration, emphasizing qualification reviews and procedural integrity.

Market Implications
The expanded expert panel is expected to accelerate reviews of high-priority applications, particularly for novel therapies and rare disease treatments. Analysts at China Healthcare Innovation Institute highlight improved review quality as a key benefit for both domestic and international developers.

Industry Impact
Pharmaceutical companies are encouraged to engage with the consultation process to ensure diverse expertise informs regulatory decisions. The move underscores China’s commitment to aligning its drug review practices with global standards.

Looking Ahead
The CDE plans to finalize the expert roster by mid-April, with the new panel expected to take effect immediately. Stakeholders should monitor how the expanded expertise influences review timelines and scientific guidance availability.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/0bb5c2dd641e1438f164ad855460b852

Policy Analysis & Guidance: China’s Drug Procurement Office Cancels Qualification for Non-Compliant Drug

China’s National Joint Procurement Office (NJPO) has canceled the centralized procurement qualification of Peramivir Injection, produced by Shanxi Yanghe Pharmaceutical Technology Co., Ltd. and entrusted to Shanxi Guorun Pharmaceutical Co., Ltd., following a regulatory crackdown on non-compliant production practices.

Policy Breakdown

Non-Compliance Identified: The National Medical Products Administration (NMPA) found the drug to violate Good Manufacturing Practice (GMP) standards, leading to a production suspension order.
Penalties Imposed: Both companies involved were added to a “blacklist” and barred from participating in national drug procurement activities until October 2026.
Substitution Mechanism: Provinces affected by the disqualification must activate backup supply procedures as per procurement guidelines.

Market Implications
The decision underscores China’s zero-tolerance policy for quality violations, potentially delaying market access for non-compliant drugs by 12–18 months. Analysts at China Healthcare Regulatory Institute highlight the move as a deterrent to substandard production practices.

Industry Impact
Pharmaceutical firms are urged to prioritize GMP compliance to avoid disruptions in supply chains and procurement qualifications. The incident serves as a reminder of the risks associated with contract manufacturing arrangements.

Looking Ahead
The NJPO is expected to intensify audits of contract manufacturing relationships, with a focus on quality system alignment. Stakeholders should monitor how substitution procedures impact regional drug availability and pricing.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2025/04/07/16524.shtml